Please provide your email address to receive an email when new articles are posted on . Patients treated with teprotumumab may be less likely to need orbital decompression. Exophthalmometry ...

As mentioned in Overview, most thyroid eye disease (TED) cases are closely related to hyperthyroidism. Approximately 85% of patients with TED develop the disease around 18 months before or after the ...

Fibroblasts from patients with TED secrete active PAPP-A and are stimulated by proinflammatory cytokines, namely tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Novel therapeutic agents may be ...

NEW ORLEANS — Teprotumumab (Tepezza) works equally well in both older and younger patients with thyroid eye disease (TED) and regardless of TED duration, new data suggest. TED is an autoimmune disease ...

—Even long after the active phase of thyroid eye disease has subsided, a multitude of challenging quality-of-life issues may persist. Several recent studies have established that the physical ...

The leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. Most patients with thyroid eye ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza, Amgen) as the first treatment to be licensed in the UK for adults with moderate-to-severe thyroid eye ...

Doses of Tepezza are given by an intravenous infusion through a blood vessel in your arm. This infusion is usually given at a hospital, health care provider’s office, or infusion center. Sometimes you ...

Thyroid eye disease is a chronic autoimmune disorder causing inflammation in the muscles and other tissues behind the eye. It can lead to other eye complications, including glaucoma. Thyroid eye ...